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RESULTS: The OPFx cohort (n = 7626) and a 1 :1 matched
control group with osteoporosis, but without a fracture were
identiﬁed. The OPFx cohort was 85.8% female, had an average
age of 65, were 53.2% White and 11.1% Asian, and 48.9% were
dual-eligible for Medicare. There were signiﬁcant increases (all
p < 0.05) from the pre-period to study-period for this cohort in
the proportion that had at least one hospital admission (12.0%
vs. 22.3%), nursing home admission (8.7% vs. 18.2%) or ER
visit (28.2% vs. 45.9%); in contrast, the control cohort had very
little variation in utilization. The regression-adjusted incremen-
tal cost in the year following fracture was estimated at $4007
per osteoporosis patient. The estimated incremental cost was
$5370 for the subset of patients who were dual-eligible. CON-
CLUSIONS: Osteoporosis-related fractures exhibit a tremen-
dous humanistic and economic toll in patients. The economic
burden of OPFx on state Medicaid budgets is substantial. Pre-
ventative strategies for avoiding fractures could help ameliorate
some of this burden.
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OBJECTIVES: To estimate impact of cardiovascular events on
annual health care costs in newly diagnosed type-2 diabetes
patients. METHODS: Patients with newly diagnosed type-2 dia-
betes (index event) between January, 1999 and December, 2001
were identiﬁed from an employer claims database using ICD-9
codes. In the absence of a diagnosis, patients were included 
if they had at least two claims for oral hypoglycemics in a 
six-month period. A cardiovascular event was deﬁned as emer-
gency/inpatient claims for one or more of 16 cardiovascular com-
plications identiﬁed. Patients with evidence of a cardiovascular
event in the 12 months preceding the index event were excluded.
Costs were adjusted to 2002 dollars and then annualized. A log-
transformed model was developed to estimate the impact of 
cardiovascular events on annual health care costs. Patient 
demographics, co-morbidities, concomitant medications and
treatment groups were used as covariates. RESULTS: Based on
the selection criteria, the study cohort included 57,563 newly
diagnosed type-2 diabetes patients. The average patient age was
59.5 years and 50.7% were female. The mean adjusted annual
health care cost per patient was $11,994.33. Annual cost was
distributed across emergency room (2.49%), outpatient (45%),
inpatient (29.75%) and prescription drug (22.54%) costs.
Annual costs were signiﬁcantly greater in women (17.1%; p <
0.001) and signiﬁcantly lower in absence of any complications
(-14.5%; p < 0.001). About 12% of the type-2 diabetes patient
population reported one or more cardiovascular events. The
mean number of cardiovascular events per patient per year 
was 0.067. A cardiovascular event contributed to a signiﬁcant
increase (129%; p < 0.001) in annual costs. The average annual
cost per patient ranged from $9,507 (zero CV event) to $65,130
(5+ CV events). CONCLUSIONS: Cardiovascular events con-
tribute signiﬁcantly to health care costs in the type-2 diabetes
patients.
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OBJECTIVE: To evaluate the sensitivity of overactive bladder
(OAB) medical cost estimates to estimation technique.
METHODS: Data were from de-identiﬁed medical and phar-
macy claims of patients aged ≥18 years enrolled in a large US
health plan. Inclusion criteria were: ≥1 claim with OAB-related
ICD-9-CM codes recorded between January 1, 2001 and Decem-
ber 31, 2002; initiation of immediate-release oxybutynin (OXY
IR), extended-release OXY (OXY ER), or extended-release
tolterodine (TOL ER); and continuous health plan coverage 
for six months before and 12 months after treatment initiation.
Models were based on logged 12-month medical costs, with
treatment, sex, age, geographic region, baseline costs, and
comorbidities as covariates. Estimation techniques compared
were ordinary least squares (OLS) with smearing estimator, treat-
ment regressions estimating the correlation between cost and
treatment, and two-stage instrumental variables (IV) regressions.
Selectivity-corrected models were estimated for OXY IR and
OXY ER, with TOL ER as the referent. RESULTS: Association
of treatment with cost varied with estimation technique. Com-
paring costs of TOL ER and OXY ER, coefﬁcients were OLS,
0.582 (t = 1.86, p = 0.063); treatment regression, 1.108 (Z =
3.93, p < 0.001); IV regression, 1.878 (Z = 3.27, p = 0.001). A
negative correlation between treatment and cost (p, -0.3842, 
p < 0.001) suggested that OLS estimates underestimated cost 
differences between TOL ER and OXY ER therapies. OXY ER
patients had one-year predicted medical costs 191% higher
(treatment regression) or 455% higher (IV regressions) than 
did TOL ER patients. The treatment regression correlation
between the TOL ER and OXY IR treatment groups was sig-
niﬁcant and negative, suggesting that OLS also underestimated
differences in cost between those cohorts. Treatment regression
analysis revealed that costs for OXY IR patients were 48%
higher than those for TOL ER patients. CONCLUSIONS:
Failing to adjust for selection bias when comparing OAB treat-
ment costs may lead to biased estimates of cost differences
between therapies.
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OBJECTIVE: Atrial ﬂutter (AFL) is a prevalent arrhythmia
among the elderly. While numerous clinical studies have shown
the safety and efﬁcacy of cardiac ablation, the ﬁrst-line approach
still varies among physicians. The study objective is to assess the
cost-utility of catheter ablation as ﬁrst-line treatment of typical
isthmus dependent AFL. METHODS: The incremental cost-
effectiveness of catheter ablation relative to cardioversion and
drug therapy was analyzed over various time horizons up to ﬁve
years using a decision analytic Markov model (DATA 4.0TM,
TreeAge Software Inc.). Costs were based on a third party payer’s
perspective using 2004 Medicare reimbursement schedules and
discounted average wholesale drug prices. Model parameters,
adverse event rates, and utility weight estimates were obtained
from published clinical trials. Costs and utilities were discounted
at 3% annually and sensitivity analyses were performed. The
model analyzed the outcomes and resource utilization of a hypo-
thetical cohort of patients with typical isthmus-dependent AFL.
RESULTS: Ablation consistently produced greater quality-
adjusted life years (QALYs) compared to cardioversion and
drugs in analyses of one to ﬁve years (0.78 to 3.57 vs. 0.66 to
2.93 QALYs). While initial treatment costs are higher for abla-
tion compared to cardioversion and drug therapy, ablation
